Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Atherosclerosis（2019）
摘要
Image 1
更多查看译文
关键词
PCSK9,Alirocumab,lipoprotein(a),Low-density lipoprotein cholesterol,Cardiovascular risk,Cholesterol-lowering drugs
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要